LeJeune Puetz Investment Counsel LLC Buys New Position in Eli Lilly and Co (LLY)

LeJeune Puetz Investment Counsel LLC bought a new stake in shares of Eli Lilly and Co (NYSE:LLY) during the fourth quarter, Holdings Channel reports. The institutional investor bought 1,850 shares of the company’s stock, valued at approximately $136,000.

A number of other hedge funds have also made changes to their positions in LLY. Ronna Sue Cohen increased its stake in shares of Eli Lilly and by 0.3% in the third quarter. Ronna Sue Cohen now owns 2,722 shares of the company’s stock worth $218,000 after buying an additional 9 shares in the last quarter. Tarbox Group Inc. increased its stake in shares of Eli Lilly and by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock worth $124,000 after buying an additional 11 shares in the last quarter. First Citizens Bank & Trust Co. increased its stake in shares of Eli Lilly and by 0.3% in the third quarter. First Citizens Bank & Trust Co. now owns 5,920 shares of the company’s stock worth $476,000 after buying an additional 18 shares in the last quarter. Strategic Financial Group LLC increased its stake in shares of Eli Lilly and by 0.5% in the third quarter. Strategic Financial Group LLC now owns 3,449 shares of the company’s stock worth $277,000 after buying an additional 18 shares in the last quarter. Finally, Alpha Windward LLC increased its stake in shares of Eli Lilly and by 0.9% in the third quarter. Alpha Windward LLC now owns 2,133 shares of the company’s stock worth $171,000 after buying an additional 19 shares in the last quarter. Hedge funds and other institutional investors own 75.15% of the company’s stock.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Shares of Eli Lilly and Co (NYSE:LLY) opened at 84.06 on Tuesday. The firm has a market capitalization of $88.34 billion, a PE ratio of 32.58 and a beta of 0.30. Eli Lilly and Co has a 12-month low of $64.18 and a 12-month high of $86.14. The company’s 50-day moving average price is $80.89 and its 200-day moving average price is $77.08.

Eli Lilly and (NYSE:LLY) last posted its earnings results on Tuesday, January 31st. The company reported $0.95 EPS for the quarter, missing the consensus estimate of $0.98 by $0.03. Eli Lilly and had a net margin of 12.90% and a return on equity of 24.74%. The firm earned $5.76 billion during the quarter, compared to analyst estimates of $5.54 billion. During the same period in the previous year, the company posted $0.78 EPS. Eli Lilly and’s revenue for the quarter was up 7.2% compared to the same quarter last year. Analysts anticipate that Eli Lilly and Co will post $4.10 EPS for the current year.

Your IP Address:

A number of analysts have commented on the company. Credit Suisse Group AG reiterated a “buy” rating on shares of Eli Lilly and in a research report on Tuesday. Leerink Swann reiterated an “outperform” rating on shares of Eli Lilly and in a research report on Monday. Jefferies Group LLC reiterated a “buy” rating and issued a $97.00 price objective (up previously from $95.00) on shares of Eli Lilly and in a research report on Saturday, March 11th. Vetr downgraded Eli Lilly and from a “sell” rating to a “strong sell” rating and set a $70.44 price objective for the company. in a research report on Monday, February 20th. Finally, Zacks Investment Research downgraded Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Wednesday, February 15th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $86.42.

In other news, major shareholder Lilly Endowment Inc sold 230,000 shares of the company’s stock in a transaction that occurred on Friday, February 17th. The stock was sold at an average price of $80.27, for a total value of $18,462,100.00. Following the transaction, the insider now owns 125,125,804 shares of the company’s stock, valued at $10,043,848,287.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Derica W. Rice sold 11,162 shares of the company’s stock in a transaction that occurred on Friday, February 3rd. The shares were sold at an average price of $77.14, for a total value of $861,036.68. Following the completion of the transaction, the executive vice president now directly owns 58,443 shares in the company, valued at approximately $4,508,293.02. The disclosure for this sale can be found here. Insiders sold 478,162 shares of company stock worth $37,660,077 in the last ninety days. 0.20% of the stock is owned by company insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

5 Day Chart for NYSE:LLY

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Nike Suspends Relationship with Maria Sharapova
Nike Suspends Relationship with Maria Sharapova
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Rob Bironas Ex-Titans Kicker Dies in Car Crash
Ron Washington Leaves Texas Rangers Due to an Affair
Ron Washington Leaves Texas Rangers Due to an Affair
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Jonathan Dwyer Falls in Line with Other Banned NFL Players
Tony Stewart Case Going to the Grand Jury
Tony Stewart Case Going to the Grand Jury
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder
Oscar Pistorius “Blade Runner” Found Not Guilty of Murder


Leave a Reply

 
© 2006-2017 Web Breaking News.